A Phase I Open-Label Trial Evaluating The Safety, Tolerability And Pharmacokinetics Of VB-1953 For The Treatment Of Patients With Moderate To Severe Facial Acne Vulgaris When Administered As A Topical Gel.

Trial Profile

A Phase I Open-Label Trial Evaluating The Safety, Tolerability And Pharmacokinetics Of VB-1953 For The Treatment Of Patients With Moderate To Severe Facial Acne Vulgaris When Administered As A Topical Gel.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs VB 1953 (Primary)
  • Indications Acne vulgaris
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Most Recent Events

    • 07 Feb 2017 Primary endpoint (Pharmacokinetics (plasma concentration less than 1 ng/ml)) has been met, according to top-line results published in a Vyome Biosciences Media Release.
    • 07 Feb 2017 Top-Line results (n=12) published in a Vyome Biosciences Media Release.
    • 31 Oct 2016 According to Vyome Biosciences media release, company announced the administration of the first in-human dose in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top